Stringent requirement for HRD1, SEL1L, and OS-9/XTP3-B for disposal of ERAD-Ls substrates

Riccardo Bernasconi,1 Carmela Galli,1 Verena Calanca,1 Toshihiro Nakajima,3 and Maurizio Molinari1,2

1Institute for Research in Biomedicine, 6500 Bellinzona, Switzerland
2Ecole Polytechnique Fédérale de Lausanne, School of Life Sciences, 1015 Lausanne, Switzerland
3St. Marianna University School of Medicine, Kanagawa 216-8512, Japan

Sophisticated quality control mechanisms prolong retention of protein-folding intermediates in the endoplasmic reticulum (ER) until maturation while sorting out terminally misfolded polypeptides for ER-associated degradation (ERAD). The presence of structural lesions in the luminal, transmembrane, or cytosolic domains determines the classification of misfolded polypeptides as ERAD-L, -M, or -C substrates and results in selection of distinct degradation pathways. In this study, we show that disposal of soluble (nontransmembrane) polypeptides with luminal lesions (ERAD-Ls substrates) is strictly dependent on the E3 ubiquitin ligase HRD1, the associated cargo receptor SEL1L, and two interchangeable ERAD lectins, OS-9 and XTP3-B. These ERAD factors become dispensable for degradation of the same polypeptides when membrane tethered (ERAD-Lm substrates). Our data reveal that, in contrast to budding yeast, tethering of mammalian ERAD-L substrates to the membrane changes selection of the degradation pathway.

Introduction

Accumulation of misfolded proteins hampers the function of the ER and elicits a variety of stress responses that might eventually result in cell death. The capacity to rapidly remove folding-defective polypeptides from the ER lumen is therefore crucial to maintain cell homeostasis (Malhotra and Kaufman, 2007; Ron and Walter, 2007; Yoshida, 2007). Polymerogenic, misfolded proteins such as ATZ, a folding-defective, aggregation-prone mutant of the secretory protein \( \alpha \)-1-antitrypsin, and serpins are removed from the ER upon activation of multiple proteasome-dependent and proteasome-independent disposal pathways including autophagy (Perlmutter, 2006; Shen et al., 2006; Granell and Baldini, 2008; Kroeger et al., 2009; Rutledge et al., 2009). Normally, however, misfolded proteins produced in the ER are extracted from folding machineries and are dislocated across the ER membrane to be degraded by cytosolic 26S proteasomes in a series of tightly regulated events collectively defined as ER-associated degradation (ERAD; McCracken and Brodsky, 1996). Most of the polypeptides entering the ER lumen are modified with preassembled glucose-\( \alpha \)-mannose-\( \beta \)-N-acetylglucosamine-\( \alpha \)-oligosaccharides, which are covalently attached to Asn side chains in Asn-xxx-Ser/Thr sequons emerging in the ER lumen. Stepwise processing of protein-bound oligosaccharides eventually determines the fate of the covalently linked polypeptide chains (for review see Molinari, 2007). For instance, degradation of terminally misfolded glycoproteins from the ER requires extensive demannosylation of the protein-bound oligosaccharides, which precedes polypeptide dislocation across the ER membrane and degradation (Hebert and Molinari, 2007; Nakatsukasa and Brodsky, 2008; Lederkremer, 2009). Current models claim that dislocation across the ER membrane follows specific pathways regulated by luminal, transmembrane, and cytosolic complexes built around membrane-embedded E3 ubiquitin ligases (Kostova et al., 2007; Nakatsukasa and Brodsky, 2008; Ravid and Hochstrasser, 2008; Hirsch et al., 2009). In Saccharomyces cerevisiae, disposal of transmembrane proteins with cytosolic defects (ERAD-C substrates) requires intervention of the DOA10 pathway. Membrane-anchored polypeptides with transmembrane lesions (ERAD-M substrates) as well as membrane-tethered and soluble polypeptides with lesions in the ER lumen (ERAD-L substrates) are cleared from the ER.
through the HRD1 pathway (Taxis et al., 2003; Huyer et al., 2004; Vashist and Ng, 2004; Carvalho et al., 2006; Denic et al., 2006; Gauss et al., 2006; Willer et al., 2008).

The mammalian system is more complex. The mammalian ER membrane contains several E3 ubiquitin ligases. Few of them (e.g., RNF5/RMA1, TE84, TRC8, and RF2) are still poorly characterized and/or have a restricted number of substrates (Younger et al., 2006; Lerner et al., 2007; Morito et al., 2008). Therefore, certainly the different composition of the complexes built around membrane-embedded E3 ubiquitin ligases determines substrate selection, but which substrate feature is relevant to determine whether a misfolded polypeptide will preferentially use one or the other ERAD pathway is unknown.

To better understand this, we compared the requirements for efficient disposal of two canonical, N-glycosylated, membrane-anchored ERAD substrates, BACE476 (Molinari et al., 2002) and CD3-δ (Yang et al., 1998), with the requirements for efficient disposal of their variants lacking the transmembrane anchor (BACE476Δ and CD3-δΔ; Fig. 1). For all of these proteins, extensive demannosylation is required for ERAD. Our data reveal that only degradation of the soluble (nontransmembrane) variants of BACE476 and CD3-δ strictly depend on several participants of the HRD1 pathway regulating ERAD, namely the E3 ubiquitin ligase HRD1, the HRD1-associated cargo receptor SEL1L, and the ERAD lectins OS-9 and XTP3-B.

To better understand this, we compared the requirements for efficient disposal of two canonical, N-glycosylated, membrane-anchored ERAD substrates, BACE476 (Molinari et al., 2002) and CD3-δ (Yang et al., 1998), with the requirements for efficient disposal of their variants lacking the transmembrane anchor (BACE476Δ and CD3-δΔ; Fig. 1). For all of these proteins, extensive demannosylation is required for ERAD. Our data reveal that only degradation of the soluble (nontransmembrane) variants of BACE476 and CD3-δ strictly depend on several participants of the HRD1 pathway regulating ERAD, namely the E3 ubiquitin ligase HRD1, the HRD1-associated cargo receptor SEL1L, and the ERAD lectins OS-9 and XTP3-B. Disposal of the membrane-tethered variants of the same folding-defective polypeptides remained unperturbed upon inactivation of HRD1, SEL1L, and, significantly, OS-9 and XTP3-B. Thus, in contrast to yeast (Quan et al., 2008; Clerc et al., 2009), substrate demannosylation in the mammalian ER is not (only) required to generate a signal for disposal decoded by the ERAD lectins of the OS-9 family. In fact, at least when the folding-defective glycopolypeptide is tethered at the ER membrane, intervention of OS-9 and XTP3-B becomes dispensable for efficient disposal. Moreover, and again in contrast to yeast (Taxis et al., 2003; Willer et al., 2008), the presence or the absence of a membrane anchor alters selection of the disposal pathway used by ERAD-L substrates in mammalian cells. This was confirmed by the finding that the crucial dependency on components of the HRD1 pathway for degradation of NHK, another classical ERAD-L substrate (Liu et al., 1997), was substantially relieved when the protein was anchored at the ER membrane. Our data lead us to group polypeptides with structural lesions in the ER lumen in two subclasses, namely ERAD-L_{LM} substrates (for soluble ERAD-L substrates whose disposal is strictly dependent on the HRD1 pathway) and ERAD-L_{LS} substrates (for membrane-tethered ERAD-L substrates for which alternative ERAD pathways can be activated to ensure efficient disposal).
further highlight the more significant complexity and the somewhat different mechanisms regulating protein quality control in the mammalian versus the budding yeast ER.

Results

Consequences of HRD1 deletion on disposal of membrane-anchored and soluble BACE476

Availability of mouse embryonic fibroblasts (MEFs) lacking HRD1 (Yagishita et al., 2005) prompted us to assess the involvement of this membrane-embedded E3 ubiquitin ligase in disposal of folding-defective polypeptides from the ER lumen. Hrd1−/− cells were more sensitive to ER stress-induced apoptosis, but they are not under ER stress (Fig. S2 C; Yagishita et al., 2005).

Tissue-specific versions of the human β-secretase (BACE501; Vanoni et al., 2008) are among the best-characterized ERAD substrates. For example, the type I membrane glycoprotein BACE476 and its soluble variant BACE476Δ originate from alternative splicing of the BACE transcripts, resulting in a 25-residue deletion in the protein’s luminal ectodomain. This deletion prevents attainment of the native structure when the polypeptide is ectopically expressed in cultured mammalian cells (Molinari et al., 2002). BACE variants are defined as canonical ERAD substrates because their degradation requires extensive demannosylation of the protein-bound oligosaccharides (Fig. S1; Molinari et al., 2002), is accelerated in cells expressing high levels of EDEM1 and EDEM2 (Molinari et al., 2003; Oliviari et al., 2005, 2006), is delayed in cells with low content of EDEM proteins (Molinari et al., 2003), and is performed in the cytosol upon P97-facilitated extraction by 26S proteasomes (Fig. S1; Molinari et al., 2002; Wang et al., 2006).

BACE476 (Fig. 2 A) and BACE476Δ (Fig. 2 B) were individually expressed in wild-type MEFs (wt; lanes 1–3) and MEFs lacking HRD1 (Hrd1−/−; lanes 4–6). 17 h after transfection with appropriate expression plasmids, cells were pulsed for 10 min with [35S]methionine and cysteine and were subsequently chased in normal cell culture media for the times shown in Fig. 2 (A and B). At the end of each chase time, cells were detergent solubilized, and the residual amount of radiolabeled ERAD substrate was immunoisolated from postnuclear supernatants (PNSs) with specific antibodies (Fig. S2 A), separated on SDS polyacrylamide gels, and quantified.

The kinetics of BACE476 disposal was essentially the same in cells with (Fig. 2 A, lanes 1–3) and without HRD1 (Fig. 2 A, lanes 4–6). In both cell lines, only ∼30% of the initial amount of radiolabeled polypeptide was immunoinsolated from PNS after a 6-h chase (Fig. 2 A, quantification). However, HRD1 deletion substantially delayed disposal of the same protein lacking a transmembrane anchor. In fact, only ∼20% of the initial amount of BACE476Δ was immunoinsolated from lysates of wt cells after a 4-h chase (Fig. 2 B, lane 3 and quantification), whereas cells lacking HRD1 still contained ∼80% of the initial amount of labeled protein (Fig. 2 B, lane 6 and quantification). Therefore, HRD1 deletion selectively impaired disposal of the soluble variant of BACE476.

Figure 2. Involvement of HRD1 in disposal of membrane-tethered and soluble BACE476. (A) Radiolabeled BACE476 was immunoinsolated after the indicated chase times from wild-type MEFs (wt; lanes 1–3) or MEFs lacking HRD1 (Hrd1−/−; lanes 4–6). Relevant bands were quantified and plotted. (B) Same as described in A for BACE476Δ. (C) Radiolabeled BACE476Δ was immunoinsolated after the indicated chase times from cells lacking HRD1 transfected with an empty plasmid (mock; lanes 1–3), a plasmid for expression of wild-type HRD1 (lanes 4–6), or a plasmid for expression of inactive HRD1 (Hrd1−/−; lanes 7–9). Relevant bands were quantified and plotted. Error bars represent standard deviation (n = 2). Molecular mass markers are shown on the left for all gels (given in kilodaltons).

The labeled ERAD candidates had faster mobility at the end (Fig. 2, A and B, lanes 3 and 6) than at the beginning of the chase (Fig. 2, A and B, lanes 1 and 4). This is caused by the progressive demannosylation of ER-retained, misfolded polypeptides that reduces their apparent molecular weight. Extensive demannosylation interrupts futile folding attempts in the calnexin chaperone system and promotes substrate deviation in the ERAD pathway (for review see Molinari, 2007). Consistently, the progressive increase in BACE electrophoretic mobility and BACE disposal were inhibited by kifunensine, a specific inhibitor of α,1,2-mannosidases (Fig. S1, A and B, lane 3). Deletion of HRD1 substantially delayed BACE476Δ disposal without affecting the enhancement of BACE mobility, thus the extensive demannosylation that precedes BACE ERAD. This shows that, in the series of luminal events leading to BACE destruction, i.e., (a) folding attempts phase in the calnexin cycle (Molinari et al., 2002), (b) extraction from the folding machinery facilitated by substrate demannosylation (Molinari et al., 2002, 2003), (c) delivery to the ER membrane, (d) and dislocation across the ER membrane, the deletion of HRD1 only interferes with late events, as expected for a component of the dislocation machinery.

Disposal of ERAD-LS versus ERAD-LM substrates • Bernasconi et al. 225
HRD1 activity is required for efficient disposal of BACE476∆

To avoid spurious phenotypes possibly caused by uncharacterized differences between wild-type and knockout cell lines, we confirmed that HRD1 is required for efficient disposal of BACE476∆ by reproducing the experiments shown in Fig. 2 (A and B) in a single cell line. To this end, we compared degradation of BACE476∆ in Hrd1 knockout cells mock transfected (Fig. 2 C, lanes 1–3) and in the same cell line expressing an active (HRD1; Fig. 2 C, lanes 4–6; and Fig. S2 B) or inactive form (the C307S mutant HRD1*; Fig. 2 C, lanes 7–9; and Fig. S2 B; Amano et al., 2003) of HRD1. In all experiments, BACE476∆ was efficiently retained in the ER and degraded as confirmed by the lack of BACE476∆ secretion (Fig. S2 D). BACE476∆ had t1/2 > 240 min in cells lacking HRD1 (for determination of protein t1/2 see Materials and methods; Fig. 2, B [lanes 4–6] and C [lanes 1–3]). Back transfection of the active form of HRD1 accelerated disposal of BACE476∆ to a rate (t1/2 = 150 min; Fig. 2 C, lanes 4–6) approaching the disposal rate measured in wild-type cells (Fig. 2 B, lanes 1–3 and quantifications). In cells expressing the inactive form of HRD1, disposal of BACE476∆ (t1/2 > 240 min; Fig. 2 C, lanes 7–9) was as slow as in cells lacking HRD1 (Fig. 2, B [lanes 4–6] and C [lanes 1–3]). We concluded that an active HRD1 pathway is required for efficient degradation of BACE476∆ from the mammalian ER. Experiments performed to assess consequences of ectopic expression of active or inactive HRD1 on disposal of BACE476 in cells lacking this E3 ubiquitin ligase confirmed dispensability of the HRD1 activity when the same folding-defective ERAD substrate was tethered at the ER membrane (Fig. S3 A).

Consequences of HRD1 deletion on disposal of membrane-anchored and soluble CD3-δ

CD3-δ is a type I membrane glycoprotein, which is typically part of the T cell receptor–CD3 complex involved in T cell development and signal transduction. When expressed individually, the CD3-δ orphan subunit cannot attain its native structure and is degraded from the ER with mechanisms that have been thoroughly characterized. In particular, CD3-δ degradation requires demannosylation and is operated by cytosolic proteasomes (Yang et al., 1998). CD3-δ is a client of the E3 ubiquitin ligase GP78 (Fang et al., 2001; Zhong et al., 2004; Ballar et al., 2006; Chen et al., 2006; Tsai et al., 2007), and it has been reported that RFP2, another E3 ligase, contributes to its disposal (Lerner et al., 2007). Down-regulation of HRD1 does not affect CD3-δ degradation (Yang et al., 2007), although it has recently been reported that down-regulation of HRD1 might result in increased intracellular levels of GP78 (Shmueli et al., 2009; Ballar et al., 2010). Therefore, it was not unexpected that CD3-δ clearance from the ER lumen occurred with similar kinetics in wild-type cells (Fig. 3 A, lanes 1–3) and in cells lacking HRD1 (Fig. 3 A, lanes 4–6).

The anchorless variant of CD3-δ was also efficiently retained in the ER as confirmed by lack of secretion in the extracellular media (Fig. S2 E). As for the membrane-anchored version of the protein, CD3-δ disposal required demannosylation and was operated by cytosolic proteasomes. Significantly, however, deletion of the CD3-δ membrane anchor converted this GP78/RFP2 client protein to an HRD1 client. In fact, degradation of the anchorless CD3-δ was defective in cells lacking HRD1 (Fig. 3 B, lanes 4–6 and quantifications). HRD1 deletion inhibited CD3-δ disposal without affecting the extensive substrate demannosylation that signals prolonged ER retention of this folding-defective polypeptide.

As in the case of BACE476∆, to avoid spurious phenotypes possibly caused by uncharacterized differences between wild-type and knockout cell lines, we confirmed involvement of HRD1 by showing that CD3-δ disposal was defective in cells lacking HRD1 or expressing the inactive form of HRD1 (t1/2 > 120 min; Fig. 3 C, lanes 1–3 and 7–9, respectively) but progressed with wild-type kinetics (t1/2 < 60 min; Fig. 3 C, lanes 4–6) upon back transfection of active HRD1 in the knockout cells. The finding that an active HRD1 pathway is required for efficient disposal of CD3-δ but not for disposal of the same protein when associated with the ER membrane was confirmed by assessing the dispensability of HRD1 for CD3-δ disposal (Fig. S3 B).
HRD1 and GP78 requirements for disposal of membrane-tethered and soluble BACE476

So far, we showed that deletion of HRD1 significantly interferes with disposal of the anchorless variants of BACE476 and CD3-ζ (ERAD-L<sub>S</sub> substrates), leaving unaffected disposal of polypeptides with the same luminal domain, but tethered at the ER membrane (ERAD-L<sub>M</sub> substrates). This may indicate that HRD1 is not involved in disposal of membrane-anchored ERAD-L substrates or that upon HRD1 deletion, surrogate pathways regulated by other membrane-embedded E3 ligases are engaged to ensure disposal.

To verify this, we next assessed the consequences of the individual and combined down-regulation of HRD1 and GP78 in clearance of membrane-tethered and soluble BACE476 from the ER. Down-regulation of HRD1 obtained by specific RNAi (Fig. 4 A) slightly delayed disposal of BACE476 (Fig. 4 B, lanes 4–6 and quantification of siHRD1). Down-regulation of GP78 (Fig. 4 A) had no effect (Fig. 4 B, lanes 7–9 and quantification of siGP78). However, the combined inactivation of both HRD1 and GP78 (Fig. 4 A) substantially delayed BACE476 disposal (Fig. 4 B, lanes 10–12 and quantifications siHRD1 + siGP78). The delay of BACE476 disposal obtained upon combined inactivation of the HRD1 and of the GP78 pathways was comparable with the delay obtained upon cell exposure to classical ERAD inhibitors such as kifunensine or PS341 (Fig. S1 A). Collectively, these data show that GP78 can replace the inactive HRD1 and GP78 requirements for disposal of membrane-tethered and soluble BACE476 and CD3-ζ.

Figure 4. Consequences of HRD1 and GP78 down-regulation on degradation of membrane-tethered and soluble variants of BACE476 and CD3-ζ. (A) The efficiency of siRNA-based HRD1 and GP78 down-regulations were checked by immunoblotting. Tubulin is a loading control. (B) Radiolabeled BACE476 was immunoprecipitated after the indicated chase times from cells expressing a scrambled siRNA [siSCR; lanes 1–3], an siRNA targeting HRD1 [siHRD1; lanes 4–6], GP78 [siGP78; lanes 7–9], or both HRD1 and GP78 [siHRD1/siGP78; lanes 10–12]. Relevant bands were quantified and plotted. (C–E) Same as described in B for BACE476Δ, CD3-ζ, and CD3-ζΔ, respectively. Molecular mass markers are shown on the left for all gels (given in kilodaltons).
HRD1 and that, vice versa, HRD1 can replace inactive GP78 to ensure efficient disposal of BACE476.

On the contrary, HRD1 down-regulation was sufficient to delay BACE476Δ disposal to a similar extent as α1,2-mannosidases or proteasome inactivation (Fig. 4 C, lanes 4–6 and quantifications; and Fig. S1 B). Down-regulation of GP78 had no effect on BACE476Δ degradation (Fig. 4 C, lanes 7–9), and combined inactivation of the two E3 ubiquitin ligases (Fig. 4 C, lanes 10–12) had the same inhibitory effect as the individual down-regulation of HRD1 (Fig. 4 C, quantification). This is in agreement with a model claiming that the presence or absence of a membrane anchor determines requirements for disposal of ERAD-L substrates. More precisely, deletion of the membrane anchor converted BACE476 from an HRD1/GP78 client into an obligate client of the HRD1 pathway.

**HRD1 and GP78 requirements for efficient disposal of membrane-tethered and soluble CD3-δ**

Next, we assessed the contribution of HRD1 and GP78 in clearance from the ER of CD3-δ and CD3-δΔ. Down-regulation of HRD1 did not affect degradation of CD3-δ (Fig. 4 D, lanes 4–6 and quantifications). Down-regulation of GP78 did delay CD3-δ disposal (Fig. 4 D, lanes 7–9), and the additional inactivation of HRD1 did not further protect this folding-defective polypeptide from ERAD (Fig. 4 D, lanes 10–12 and quantifications). These data are consistent with findings reporting that CD3-δ is a client of the GP78 machinery (Fang et al., 2001; Zhong et al., 2004; Ballar et al., 2006; Chen et al., 2006; Tsai et al., 2007) and with data showing that CD3-δ disposal remains unaffected upon inactivation of the HRD1 pathway (Fig. 3 A; Yang et al., 2007). The incomplete inhibition of CD3-δ disposal upon inactivation of GP78 (Fig. 4 D) is consistent with data showing that at least another E3 ligase, RFP2 (Lerner et al., 2007), contributes to CD3-δ clearance from the ER lumen.

In agreement with our model predicting that changes in substrate tethering to the membrane determine selection of the ERAD pathway regulating clearance of ERAD-L substrates from the ER, HRD1 down-regulation was sufficient to substantially delay CD3-δΔ disposal (Fig. 4 E, lanes 4–6 and quantifications), whereas down-regulation of GP78 had no effect (Fig. 4 E, lanes 7–9). Combined inactivation of the two ligases (Fig. 4 E, lanes 10–12) had the same inhibitory effect on CD3-δΔ disposal as the individual down-regulation of HRD1. Thus, deletion of the membrane anchor converted CD3-δ from a GP78/RFP2 client into an obligate client of the HRD1 pathway.

**SEL1L is required for efficient disposal of ERAD-L_δ substrates**

Our data show a stringent requirement of HRD1 for degradation of the ERAD-L_δ substrates BACE476Δ and CD3-δΔ. The same polypeptides might exploit the HRD1 and/or the GP78 and/or other E3 ligases for efficient disposal when anchored at the ER membrane. The complex built around HRD1 contains several proteins that are excluded from the GP78 complex. Among them, SEL1L plays a crucial role in protein disposal by recruiting ERAD substrates either directly or indirectly through association with the ERAD lectins OS-9 and XTP3-B (Mueller et al., 2006, 2008; Christianson et al., 2008; Hosokawa et al., 2008) through association with the member of the glycosyl hydrolase 47 family EDEM1 (Cormier et al., 2009) or through association with luminal chaperones such as BiP or GRP94.

Our finding that only ERAD-L_δ substrates were strictly dependent on active HRD1 prompted us to verify the involvement of SEL1L in clearance of ERAD-L_δ versus ERAD-L_M substrates. To this end, kinetics of protein disposal was compared in mock-treated cells (Fig. 5, siSCR) and in cells with reduced expression of SEL1L (Fig. 5, siSEL1L). Down-regulation of SEL1L (Fig. 5 A) only marginally slowed disposal of the ERAD-L_M substrate BACE476 (Fig. 5 B, lanes 4–6 and quantifications) but substantially delayed degradation of the ERAD-L_M substrate BACE476Δ (Fig. 5 C, lanes 4–6 and quantifications). Similarly, down-regulation of SEL1L had no effect on degradation of the ERAD-L_M substrate CD3-δ (Fig. 5 D, lanes 4–6 and quantifications) but fully protected the anchorless variant of the same folding-defective polypeptide from degradation (Fig. 5 E, lanes 4–6 and quantifications). Collectively, these findings showed that down-regulation of SEL1L recapitulates the phenotype obtained upon deletion (Figs. 2 and 3) or down-regulation of HRD1 (Fig. 4). Inactivation of HRD1 or SEL1L had little or no effect on disposal of ERAD-L_δ substrates but dramatically interfered with clearance from the ER lumen of the same polypeptides when detached from the ER membrane (ERAD-L_M substrates).

**OS-9 and XTP3-B are interchangeable**

ERAD shuttles required for efficient disposal of ERAD-L_δ but not ERAD-L_M substrates

The mammalian splice variants of OS-9 and XTP3-B constitute a group of proteins that have lectin-like domains with homology to the mannose-6-phosphate receptor family (Munro, 2001). So far, OS-9 or XTP3-B intervention in ERAD has only been shown for the model ERAD substrates NHK or R1332 (Bernasconi et al., 2008; Christianson et al., 2008; Hosokawa et al., 2008; Mueller et al., 2008; Alcock and Swanton, 2009; Hosokawa et al., 2009). The individual down-regulation of these ERAD lectins has generally no or mild phenotypes, and attempts to establish the involvement of OS-9 or XTP3-B variants in disposal of other glycosylated folding-defective polypeptides have been unsuccessful, thus questioning their relevance as general regulators of protein disposal from the mammalian ER. Our data confirm that individual down-regulation of OS-9 (Fig. 5, A, B, and E, lanes 7–9 and quantifications) or XTP3-B (Fig. 5, A, B, and E, lanes 10–12 and quantifications) did not significantly delay disposal of BACE476, BACE476Δ, CD3-δ, and CD3-δΔ. However, combined down-regulation of OS-9 and XTP3-B specifically retarded disposal of the HRD1 client BACE476Δ (Fig. 5 C, lanes 13–15 and quantifications) to a similar extent as down-regulation of SEL1L (lanes 4–6) and HRD1 (Fig. 4 C, lanes 4–6). Combined down-regulation of OS-9 and XTP3-B also partially protected CD3-δΔ from disposal (Fig. 5 E, lanes 13–15). Thus, OS-9 and XTP3-B have redundant activities in the ER lumen.
so that their combined inactivation might be required to substantially delay disposal. NHK is an exception to this rule because individual down-regulation of OS-9 is sufficient to significantly delay ERAD (Bernasconi et al., 2008; Christianson et al., 2008). Moreover, our data show that OS-9 and XTP3-B intervention is only required for disposal of ERAD-L\(S\) substrates that must be shuttled from the ER lumen to the ER membrane-embedded HRD1 complex for efficient clearance from the ER. For this reason, we define OS-9 and XTP3-B as ERAD shuttles. Disposal of the same glycopolypeptides tethered to the ER membrane (ERAD-L\(M\) substrates) progressed unperturbed even upon substantial reduction of the cellular content of OS-9 and XTP3-B. This shows that the two ERAD shuttles do not intervene in disposal of membrane-tethered N-glycosylated polypeptides with luminal defects or that they can efficiently be replaced by a surrogate factor upon their combined inactivation (see Discussion).

Down-regulation of SEL1L and HRD1 allows identification of OS-9.1 as delivery factor for BACE476\(\Delta\)

In an attempt to identify ERAD factors interacting with ERAD-L\(S\) versus ERAD-L\(M\) substrates, BACE476\(\Delta\) was tagged with an EFRH tetrapeptide (which is recognized by \(\beta\)1, a monoclonal antibody described in Paganetti et al., 2005), whereas BACE476 was HA tagged. The two proteins were ectopically coexpressed in mock-treated cells (siSCR; Fig. 6, A and B, lane 1; Fig. S4) or in cells with reduced levels of HRD1 (Fig. 6, A and B, lane 2), GP78 (Fig. 6, A and B, lane 3), HRD1 and GP78 (Fig. 6, A and B, lane 4), SEL1L (Fig. 6, A and B, lane 6), OS-9 (Fig. 6, A and B, lane 7), XTP3-B (Fig. 6, A and B, lane 8), OS-9 and XTP3-B (Fig. 6, A and B, lane 9). Cells were lysed under conditions that preserve many substrate–chaperone interactions (Molinari et al., 2002). BACE476\(\Delta\)-\(\beta\)1 (Fig. 6 A) and BACE476-HA (Fig. 6 B) were individually immunoisolated with the appropriate anti-tag...
antibody together with their interacting partners. The amount of proteins separated in SDS-PAGE and blotted on a PVDF membrane was normalized to ensure equal loading of BACE in each lane (Fig. 6, A and B, bottom). The PVDF membrane was probed with antibodies to GRP94, BiP, and OS-9 to determine whether these ER chaperones, claimed to be involved in ERAD, were found in complexes sufficiently stable to survive the cell lysis and immunoprecipitation protocols. The case for GRP94 is unclear, as variations in the amount of this chaperone co-precipitated with BACE476Δ-β1 (Fig. 6 A) or BACE476-HA (Fig. 6 B) were too small to be considered significant. Variations were also small for BiP. However, a stabilization of BACE476Δ-BiP complexes was observed upon inactivation of HRD1 (Fig. 6 A, lane 2), HRD1 + GP78 (Fig. 6 A, lane 4), SEL1L (Fig. 6 A, lane 6), and upon combined inactivation of OS-9 + XTP3-B (Fig. 6 A, lane 9). These variations were reproducible even when BACE476Δ-β1 was individually expressed in cells subjected to transient interferences (unpublished data). Stabilization of BACE476Δ-BiP complexes upon disassembly of the HRD1 dislocan shows that BiP contributes to delivery of terminally misfolded polypeptides to this machinery.

Our analysis also revealed a significant stabilization of BACE476Δ–OS-9.1 complexes in cells subjected to HRD1 (Fig. 6 A, lane 2), HRD1 + GP78 (less evident; Fig. 6 A, lane 4), SEL1L down-regulations (Fig. 6 A, lane 6). Under the same conditions, and actually in the same cells because BACE476Δ-β1 and BACE476-HA were coexpressed, we were unable to detect stabilization of complexes between BACE476 and the ER chaperones tested (Fig. 6 B).

The stabilization of BACE476Δ–OS-9.1 complexes (and possibly of BACE476Δ–XTP3-B complexes [an antibody to detect endogenous XTP3-B is unfortunately not available] when SEL1L or HRD1 is not available for substrate delivery) is consistent with a sequential involvement of these components during channeling of BACE476Δ into the cytosol for disposal.

**Disposal of the classical ERAD-L$_{g}$ substrate NHK and of its two ERAD-L$_{M}$ variants, NHK$_{BACE}$ and NHK$_{CD3}$:**

So far, we showed that deletion of the membrane anchor of ERAD-L substrates confers a strong dependency on the HRD1 machinery independent of the mechanisms regulating disposal of the membrane-tethered version of the proteins under investigation. To challenge our model, we decided to determine requirements for disposal of a soluble ERAD substrate and to verify how requirements would change upon addition of a transmembrane anchor. To this end, we selected a classical ERAD-L substrate, the NHK variant of the secretory protein α1-antitrypsin (Liu et al., 1997). As previously shown in other cell lines (Bernasconi et al., 2008), we confirm that a fraction of NHK escapes ER retention and is secreted extracellularly (~15% of the labeled protein in HeLa cells; Fig. S2 F). The expectations were that disposal of this ERAD-L$_{g}$ protein should substantially be delayed upon inactivation of the E3 ligase HRD1 and that the strict dependency on HRD1 should be relieved when the folding-defective polypeptide is converted in a membrane-tethered ERAD-L$_{M}$ protein. Reduction of the intralumenal level of HRD1 (Fig. 7 A, lanes 4–6) substantially inhibited NHK degradation without affecting secretion of the protein (Fig. S2 F). The combined inactivation of the GP78 pathway did not further protect the protein from disposal (Fig. 7 A, lanes 10–12). The intervention of HRD1 was not surprising because both SEL1L (Christianson et al., 2008; unpublished data) and OS-9 (Bernasconi et al., 2008; Christianson et al., 2008) have been shown to participate in NHK disposal. Thus, NHK behaves as a bona fide ERAD-L$_{M}$ protein as defined above, which shows strict dependency on the HRD1 pathway for disposal.

Tethering of NHK at the ER membrane was obtained by appending the membrane anchor of BACE501 (NHK$_{BACE}$; Fig. 1) or the membrane anchor of CD3-δ (NHK$_{CD3}$; Fig. 1) at the C terminus of NHK (see Materials and methods). The membrane anchor of BACE501 does not contain misfolded or retention signals. Consistently, BACE501 is efficiently transported to the cell surface when the protein is ectopically expressed in cultured cells (Vanoni et al., 2008). However, it is not entirely clear whether the transmembrane domain of CD3-δ is free of misfolding signal. Anchoring of NHK$_{BACE}$ and of NHK$_{CD3}$ at the ER membrane was confirmed by subcellular fractionation as described previously (Fig. S5, A and B, respectively; Olivari et al., 2005). Both proteins were degraded from cells with slightly faster kinetics compared with their soluble counterpart (Fig. 7, A [NHK], B [NHK$_{BACE}$], and C [NHK$_{CD3}$]; compare lanes 1–3). Degradation was efficiently
inhibited upon inactivation of ER mannosidases and cytosolic proteasomes (unpublished data). In agreement with our model, conversion of NHK in an ERAD-L{s} substrate substantially relieved HRD1 dependency. In fact, disposal of both NHK_{BACE} (Fig. 7 B) and NHK_{CD3}{δ} (Fig. 7 C) was unaffected upon reduction of the intraluminal level of HRD1. Disposal of the membrane-tethered versions of NHK was only partially delayed upon inactivation of both the HRD1 and GP78 pathways (Fig. 7, B and C, lanes 10–12), hinting at the possible intervention of alternative ERAD pathways in disposal of NHK when anchored at the ER membrane.

Discussion

The protein folding, quality control, and disposal machineries operating in the mammalian ER lumen determine the fate of thousands of gene products, each one characterized by unique structural, biophysical, and biochemical properties. The covalent addition of preassembled glucose_{1}-mannose_{2}-N-acetylglucosamine_{2}-oligosaccharides on nascent polypeptide chains (Fig. 8 A) and their processing generate unique signals decoded by ER-resident lectins, glucosyl transferases, and glycosyl hydrolases that determine prolongation or interruption of folding and onset of disposal (Aebi et al., 2009; for review see Molinari, 2007). Current models claim that a series of α1,2-mannosidases (MnsIp and HmIp in S. cerevisiae; Quan et al., 2008; Clerc et al., 2009), ERManI, EDEM proteins, and/or Golgi mannosidases in mammalian cells (Liu et al., 1997; Hirao et al., 2006; Olivari et al., 2006; Hosokawa et al., 2007; for review see Aebi et al., 2009) slowly remove terminal α1,2-bonded mannose residues (Fig. 8 A, dark green) from oligosaccharides displayed on terminally misfolded polypeptides. Demannosylated oligosaccharides recruit ERAD lectins such as Yos9p in S. cerevisiae and OS-9 and XTP3-B splice variants in mammals (Bernasconi et al., 2008; Christianson et al., 2008; Hosokawa et al., 2008, 2009; Mueller et al., 2008; Quan et al., 2008; Tamura et al., 2008; Wang and Ng, 2008; Alcock and Swanton, 2009; Clerc et al., 2009). ERAD lectins and luminal chaperones such as BiP, GRP94, and protein disulfide isomerase deliver terminally misfolded polypeptides to dislocons at the ER membrane. Dislocons contain a membrane-embedded E3 ubiquitin ligase and several adaptor molecules with substrate-recognition/modifying domains facing the luminal and/or cytosolic side of the ER membrane. Altogether, these multimeric protein complexes regulate the export of terminally misfolded polypeptides across the ER membrane and their polyubiquitylation that facilitates proteasomal intervention (Kostova et al., 2007; Nakatsukasa and Brodsky, 2008; Ravid and Hochstrasser, 2008; Hirsch et al., 2009).

In S. cerevisiae, the primary role of demannosylation of folding-defective polypeptides is the exposure of the α1,6-bonded mannose residue j (Fig. 8 A) that recruits the ERAD lectin Yos9p (Quan et al., 2008; Clerc et al., 2009). Our data show that in mammalian cells, even though demannosylation is required for disposal of N-glycosylated ERAD-L{s} for soluble; detached from the ER membrane) and ERAD-L{M} (for membrane tethered) substrates, OS-9 and XTP3-B are only required for disposal of ERAD-L{s} substrates. We have defined OS-9 and XTP3-B as ERAD shuttles because they associate with soluble, misfolded polypeptides in the ER lumen and deliver them at dislocons embedded in the ER membrane. Our data show that OS-9 and XTP3-B are interchangeable in this function, thus
explaining the mild, if any phenotype caused by their individual inactivation reported so far in the literature.

At least for ERAD-L_M substrates, the primary role of demannosylation might not be the recruitment of OS-9 and XTP3-B because the two ERAD shuttles are dispensable for disposal of N-glycosylated polypeptides tethered at the ER membrane. One could envision that another lectin decodes the ERAD signal generated upon demannosylation of ERAD-L_M substrates when OS-9 and XTP3-B are not available. If this would hold true, this yet to be characterized factor cannot act as surrogate ERAD lectin for soluble, misfolded glycopolypeptides.

Alternatively, the primary role of demannosylation of ERAD-L_M substrates could be to elicit extraction of folding-defective polypeptides from the calnexin chaperone system, which is a rate-limiting step in disposal of N-glycosylated proteins (for review see Molinari, 2007). The mammalian ER contains the quality control enzyme UDP-glucose–glycoprotein glucosyl transferase (UGT1; Parodi, 2000). The activity of UGT1 preserves the glucose residue from the folding machinery and is crucial to initiate a series of events eventually leading to polypeptide disposal. Consistently, pharmacologic inactivation of 1,2-mannosidases (Molinari et al., 2002) or reduction of their activity reported so far in the literature.

The mammalian ER membrane hosts several E3 ubiquitin ligases that might potentially contribute to dislocation/disposal of misfolded proteins from the ER (Kostova et al., 2007; Nakatsukasa and Brodsky, 2008; Ravid and Hochstrasser, 2008; Hirsch et al., 2009). Individual or combined inactivation of two of them, namely HRD1 and GP78, was sufficient to significantly delay disposal of classical ERAD-L substrates such as BACE, CD3-δ, and NHK variants. For folding-defective polypeptides detached from the ER membrane (ERAD-L sub- strates), efficient disposal required HRD1, SEL1L, and OS-9 or XTP3-B. The stringent requirement for components of the HRD1 pathway was relieved when the very same luminal domains were tethered to the ER membrane. Thus, ERAD-L_M substrates do use, or can eventually engage, alternative ERAD pathways when the HRD1 pathway has been shut down. Such complexity is absent or has not been reported so far in the case of S. cerevisiae in which soluble and membrane-tethered ERAD-L substrates are degraded by a unique pathway built around the E3 ubiquitin ligase Hrd1p (Taxis et al., 2003; Vashist and Ng, 2004; Carvalho et al., 2006; Willer et al., 2008).

It can be envisioned that access to membrane-embedded dislocons might be facilitated by lateral diffusion in the lipid bilayer when folding-defective polypeptides are tethered to the ER membrane. However, misfolded proteins floating in the ER lumen might be more dependent on luminal ERAD shuttles (e.g., OS-9 and XTP3-B) that direct them from the ER lumen to dislocons embedded in the ER membrane. HRD1 accessory factors such as OS-9, XTP3-B, and their membrane receptor SEL1L are excluded from complexes containing GP78 or other E3 ubiquitin ligases (Hosokawa et al., 2008; Morito et al., 2008; Alcock and Swanton, 2009). Thus, the HRD1 complex seems better equipped to recruit soluble folding-defective polypeptides at the ER membrane.
Notably, misfolded proteins lacking a transmembrane anchor might fall outside the ERAD-L₃ group and show little or no dependency on conventional ERAD shunts that would channel them to the HRD1 complex. For example, ATZ and serpins do not belong to the ERAD-L₃ group because they form polymeric deposits that cells remove from the ER by activating multiple proteasome-dependent and proteasome-independent disposal pathways (see Introduction;Perlmutter, 2006;Shen et al., 2006;Granell and Baldini, 2008;Kroeger et al., 2009;Rutledge et al., 2009). Another example is ApoB, a protein that lacks a transmembrane anchor but is actually membrane associated in the lipid-ligand–deficient state that triggers its disposal (Brodsky and Fisher, 2008), and as such, may engage alternative, ERAD shuttle–independent disposal pathways.

It remains to be established what determines the ERAD pathway selection for ERAD-L₃ substrates. For example, why membrane-anchored canonical ERAD substrates such as CD3-δ (Figs. 3–5) require GP78 and/or RFP2 for efficient disposal (Fang et al., 2001;Zhong et al., 2004;Baffar et al., 2006;Chen et al., 2006;Lerner et al., 2007;Tsai et al., 2007), whereas others such as BACE476 (Figs. 2, 4, and 5), NHK_{BACE}, and NHK_{CD3δ} (Fig. 7) can use the HRD1, the GP78, and possibly other pathways. Certainly, our observations are consistent with the emerging picture that protein quality control in the mammalian ER conserves regulatory factors and basic mechanisms operating in the ER of the budding yeast but is characterized by additional levels of complexity. This is probably required to ensure efficiency of protein biogenesis and maintenance of homeostasis in the context of multicellular systems.

**Materials and methods**

**Expression plasmids, antibodies, and inhibitors**

The pCIneo plasmids encoding for CD3-δ and XTP3-B were provided by S. Fang [University of Maryland Biotechnology Institute, Medical Biotechnology Center, Baltimore, MD] and C. Niehrs [German Cancer Research Center, Heidelberg, Germany], respectively. Plasmids for expression of BACE, NHK, and HRD1 variants were described previously (Molinari et al., 2003;Yagishita et al., 2005;Bernasconi et al., 2008).

CD3-δ was prepared by inserting a stop codon (primer sequence: 5′-GACGCAAGCATTGAGTCAGCTGACGCTGCTGATCATCCTC-3′) before the membrane anchor of CD3-δ using the site-directed mutagenesis kit (Agilent Technologies). The membrane-termed variants of NHK_{BACE} and NHK_{DOU} were generated by appending at the protein C terminus the amino acids PQDTSEMITAIY/VMAACIFML-PICM/CQGRWCRLCRQHDDFADSLSSK (which correspond to residues 448–501 of BACE501) or VELDSGTA GVIFCIDIATLALGVYCCAGHTETGRPSGAAEAVQAKNILEQGDREDQGTSILGRNWPKNKSS (which correspond to residues 96–173 of CD3-δ). Transect membrane segments are italicized. DNA preparations were obtained using commercially available purification kits (Sigma-Aldrich). The nucleotide sequences of all plasmids were verified on both strands. Antibodies to BACE, NHK, and Kidney Diseases, National Institutes of Health, Bethesda, MD) and H. Ploegh (Whitehead Institute for Biomedical Research, Cambridge, MA). Antibodies to BiP, EDEM1, and GRP94 were obtained from Santa

---

**Cell Lines, transient transfections, RNAs, metabolic labeling, immunoprecipitations, immunoblots, and analysis of data**

Hrd1-/- and wild-type MEF cells were grown in DME supplemented with 10% FBS. Cells at 80–90% confluence in a 6-cm tissue culture plate were transfected with the expression plasmid of interest (4 µg for single transfections and 6 µg total DNA for double transfections) using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Experiments were generally performed 17 h after transfection. Expression of all proteins has been confirmed by immunoprecipitation (Fig. S2). For siRNA-based interference, HeLa cells were grown in MEM Alpha supplemented with 10% FBS. Cells at 50% confluence in a 3.5-cm tissue culture plate were transfected with 50 pmol/dish siRNA duplex (Applied Biosystems) using Lipofectamine 2000 according to the manufacturer’s instructions. 4 h after transfection, the medium was replaced with MEM Alpha supplemented with 1% nonessential amino acids (Invitrogen). 30 h after siRNA transfection, cells were transfected with the expression plasmids of interest. Experiments were performed 48 h after transfection. siRNA targeting sequences used are as follows: HRD1, 5′-GGGUAGGGGCAAGUGUGUUC-3′; GP78, 5′-AGCAGAUCAAGCAGUCCUUU-3′; SEL1L, 5′-GGCUAAUGCU GUCCGCUAAAG-3′; OS-9, 1 and OS-9, 2, 5′-CAUCAUCAGGAGA CAGAG-3′; XTP3-B1 and XTP3-B2, 5′-AGCAGUGUCCUUCAAGAAA-3′.

When detection of endogenous target proteins was impossible, the efficiency of siRNA was confirmed by the significant reduction in expression of ectopically expressed targets (i.e., HRD1, GP78, and XTP3-B). 18 h after transfection, cells were starved for 20 min in Met/Cys-free medium, followed by 10 min with 50 µM of cytosolic [35S]Met/Cys, and chased for the indicated times with MEM Alpha supplemented with 5 mM cold Met/Cys. PNS was prepared by solubilization of cells in 400 µl of 0.5 µM disulfide 2% CHAPS (Anatrace) in Hepes-buffered saline (HBS), pH 6.8, containing 20 mM Nethylmaleimide and protease inhibitors. CHAPS-insoluble material was separated by centrifugation at 10,000 g for 10 min. Immunoprecipitations were performed by adding protein A beads (1:10 wt/vol swollen in HBS; Sigma-Aldrich) with the selected antibody and incubated for 2 h at 4°C.

Immunoprecipitates were extensively washed (three times for 10 min) with 0.5% CHAPS in HBS, resuspended in sample buffer, boiled for 5 min, and finally separated in SDS-PAGE. Gels were exposed to films (BioMax; Kodak) and scanned with a scanner (Agfa). Relevant bands were quantified by ImageQuant software (Molecular Dynamics). Because of the number of Petri dishes that can be handled in parallel, to analyze all conditions in a single transfection round, we had to perform three-point kinetics. Protein half-lives were confirmed by separate, independent experiments using additional chase times. Immunoblots were performed using the SNAP i.d. protein detection system (Millipore). All primary antibodies were used at 1:200–1:333 dilutions. Secondary antibodies were HRP conjugated and used at 1:10,000 dilutions. The ECL Plus detection system was obtained from GE Healthcare.

**Subcellular fractionation and separation of membrane versus luminal content**

Metabolically labeled cells expressing NHK_{BACE} and NHK_{DOU} were extensively washed with isobutonic buffer and resuspended in 800 µl of homogenization buffer (10 mM triethanolamine, 10 mM acetic acid, 250 mM sucrose, 20 mM NEM, 1 mM EDTA, and a cocktail of protease inhibitors, pH 7.4; Oliviari et al., 2005). Cells were broken with 10 passages through a 25G1 needle. After nuclear supernatants were subjected to ultracentrifugation (45 min at 200,000 g in TLA 120.2), the endomembrane-containing pellet was extensively washed, resuspended in 500 µl 100 mM Na2CO3, and incubated for 25 min on ice for carbonate extraction. After an additional ultracentrifugation step (45 min for 200,000 g), the supernatant was harvested. The endomembrane fraction was washed once with 100 mM Na2CO3 (35 min at 200,000 g) and resuspended in 800 µl of lysis buffer. Insoluble material was removed after 25 min on ice by 10 min centrifugation at 200,000 g. The ER luminal content and the endosomal fraction were subjected to immunoprecipitation against calnexin, calreticulin, and NHK_{BACE} or NHK_{DOU}.

**Semiautomatical RT-PCRs**

MEF cells were mock treated or incubated for 12 h with 2.5 µg/ml tunicamycin. Cells were lysed in TRIzol reagent (Invitrogen), and RNA was isolated according to the instructions of the manufacturer. 2 µg RNA was used for cDNA synthesis using reverse transcription (SuperScriptII; Invitrogen), and the transcriptional efficiency of the resulting cDNA was confirmed with the appropriate primers (NHKop, 5′-AACAGATGAGCACTGACTG-3′; reverse primer, 5′-AACAGATGAGCACTGACTG-3′; forward).
Caramelo, J.J., and A.J. Parodi. 2008. Getting in and out from calnexin/Calreticulin cycles. J. Cell. Physiol. 215:515–523.

Chen, B., J. Mariano, Y.C. Tsai, A.H. Chan, M. Cohen, and A.M. Weissman. 2006. gp78 and ERAD-L, a lectin required for glycoprotein endoplasmic reticulum-associated degradation, recognizes mannose-trimmed N-glycans. J. Biol. Chem. 281:9650–9658.

Clerc, S., C. Hirsch, D.M. Oggier, M. Helenius, and M. Molinari. 2006. The tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc. Natl. Acad. Sci. USA. 98:14422–14427. doi:10.1073/pnas.251401598.

Denic, V., E.M. Quan, and J.S. Weissman. 2006. A luminal surveillance complex that selects misfolded glycoproteins for ER-associated degradation. Cell. 126:349–359. doi:10.1016/j.cell.2006.05.045.

Denk, W., M. Heumann, and D.B. Brachman. 2002. Imaging of ER and Golgi compartments with fluorescent ubiquitin fusion proteins. Trends Biochem. Sci. 27:371–376. doi:10.1016/s0968-0004(02)02248-6.

Deng, X., S. Fang, C. Yang, J.P. Jensen, S. Tiwari, and A.M. Weissman. 2001. The tumor autocrine motility factor receptor gp78, a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc. Natl. Acad. Sci. USA. 98:14422–14427. doi:10.1073/pnas.251401598.

Deng, X., S. Fang, C. Yang, J.P. Jensen, S. Tiwari, and A.M. Weissman. 2001. The tumor autocrine motility factor receptor gp78, a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc. Natl. Acad. Sci. USA. 98:14422–14427. doi:10.1073/pnas.251401598.

References

We thank S. Fang, C. Niehrs, H. Ploegh, Y. Ye, and A.M. Weissman (Center for Cancer Research, National Cancer Institute, Frederick, MD) for sharing reagents and advice. We also give a special thanks to D. Prescotto, C. Capra, L. Brambilla, T. Pertel, P. Paganetti, G. Noseda, and S. Monti.

M. Molinari is supported by grants from The Foundation for Research on Neurodegenerative Diseases, Onelife Advisors SA, The Swiss National Center of Competence in Research on Neural Plasticity and Repair, The Swiss National Science Foundation, TheSynopsis Foundation, and The Bangerter-Rhyner Foundation.

Submitted: 7 October 2009
Accepted: 23 December 2009

Aebi, M., R. Bernasoni, S. Clerc, and M. Molinari. 2009. N-glycan structures: recognition and processing in the ER. Trends Biochem. Sci. doi:10.1016/j.tibs.2009.10.001.

Alcock, F., and E. Swanton. 2009. Mammalian OS-9 is upregulated in response to endoplasmic reticulum stress and facilitates ubiquitination of misfolded glycoproteins. J. Mol. Biol. 385:1032–1042. doi:10.1016/j.jmb.2008.11.045.

Amano, T., S. Yamasaki, N. Yagishita, S. Tsuchimochi, H. Shin, K. Kawahara, S. Aratani, H. Fujita, L. Zhang, R. Ikeda, et al. 2003. Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy. J. Biol. Chem. 281:10588–10594. doi:10.1074/jbc.M302772200.

Barloy, Y., P. Shen, H. Yang, and S. Fang. 2006. The role of a novel gp78-like protein containing protein-interacting motif of gp78 in endoplasmic reticulum-associated degradation. J. Biol. Chem. 281:35359–35368. doi:10.1074/jbc.M603355200.

Barloy, P., A.U. Orcs, H. Yang, and S. Fang. 2010. Differential regulation of CPTD/DELTA58 degradation by ubiquitin ligases gp78 and Hrd1. Int. J. Biochem. Cell Biol. 42:167–173. doi:10.1016/j.biocel.2009.10.005.

Bernasoni, R., T. Pertel, J. Luban, and M. Molinari. 2008. A dual task for the Xbp1-responsive OS-9 variants in the mammalian endoplasmic reticulum: inhibiting secretion of misfolded protein conformers and enhancing their disposal. J. Biol. Chem. 283:16446–16454. doi:10.1074/jbc.M802272200.

Birdskey, J.L., and E.A. Fischer. 2008. The many intersecting pathways underlying apolipoprotein B secretion and degradation. Trends Endocrinol. Metab. 19:254–259. doi:10.1016/j.tem.2008.07.002.

Cao, J., J. Wang, W. Qi, H.H. Miao, J. Wang, L. Ge, R.A. DeBose-Boyd, J.J. Tang, B.L. Li, and B.L. Song. 2007. Udh1 is a cofactor of gp78 and plays a key role in cholesterol metabolism by regulating the stability of HMG-CoA reductase. Cell Metab. 6:115–128. doi:10.1016/j.cmet.2007.07.002.

Caramelo, J.M., and J.J. Parodi. 2008. Getting in and out from calnexin/calreticulin cycles. J. Biol. Chem. 283:10221–10225. doi:10.1074/jbc.R700048200.

Carvalho, P. V, Goder and T.A. Rapoport. 2006. Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER proteins. Cell. 126:361–373. doi:10.1016/j.cell.2006.05.043.

Cattaneo, M., M. Otse, C. Fagioli, S. Martino, L.V. Lotti, R. Sitia, and I. Biiuno. 2008. SEL1L and HRD1 are involved in the degradation of un-assembled secretory Ig-mu chains. J. Cell. Physiol. 215:794–802. doi:10.1002/jcp.21364.

Chen, B., J. Mariano, Y.C. Tsai, A.H. Chan, M. Cohen, and A.M. Weissman. 2006. Table 3: activity of a human endoplasmic reticulum-associated degradation E3, gp78, requires its Cue domain, RING finger, and an E2-binding site. Proc. Natl. Acad. Sci. USA. 103:341–346. doi:10.1073/pnas.0506681103.

Christiansen, J.C., T.A. Shaler, R.E. Tyler, and R.R. Kopito. 2008. OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase complex for ERAD. Nat. Cell. Biol. 10:272–282. doi:10.1038/ncb1689.
Rovaltide, A.C., W. Qiu, R. Zhang, R. Kohen-Avramoglu, N. Nemati-Gorgani, and K. Adeli. 2009. Mechanisms targeting apolipoprotein B100 to proteasomal degradation: evidence that degradation is initiated by BIP binding at the N terminus and the formation of a p97 complex at the C terminus. Arterioscler. Thromb. Vasc. Biol. 29:579–585. doi:10.1161/ATVBAHA.108.181859.

Shen, Y., P. Ballar, and S. Fang. 2006. Ubiquitin ligase gp78 increases solubility and facilitates degradation of the Z variant of alpha-1-antitrypsin. Biochem. Biophys. Res. Commun. 349:1285–1293. doi:10.1016/j.bbrc.2006.08.173.

Shmueli, A., Y.C. Tsai, M. Yang, M.A. Braun, and A.M. Weissman. 2009. Targeting of gp78 for ubiquitin-mediated proteasomal degradation by Hrd1: cross-talk between E3s in the endoplasmic reticulum. Biochem. Biophys. Res. Commun. 370:758–762. doi:10.1016/j.bbrc.2009.10.045.

Song, B.L., N. Sever, and R.A. DeBose-Boyd. 2005. Gp78, a membrane-anchored ubiquitin ligase, associates with Insig-1 and couples sterol-regulated ubiquitination to degradation of HMG-CoA reductase. Mol. Cell. 19:829–841. doi:10.1016/j.molcel.2005.03.005.

Stagg, H.R., M. Thomas, D. van den Boomen, E.J. Wiertz, H.A. Drabkin, R.M. Gemmill, and P.J. Lehner. 2009. The TRC8 E3 ligase ubiquitinates MHC class I molecules before dissolution from the ER. J. Cell Biol. 186:685–692. doi:10.1083/jcb.200906110.

Tamura, T., J.H. Cormier, and D.N. Hebert. 2008. Sweet bysses of ERAD. Trends Biochem. Sci. 33:298–300. doi:10.1016/j.tibs.2008.04.013.

Taxis, C., R. Hitt, S.H. Park, P.M. Deak, Z. Kostova, and D.H. Wolf. 2003. Use of modular substrates demonstrates mechanistic diversity and reveals differences in chaperone requirement of ERAD. J. Biol. Chem. 278:35903–35913. doi:10.1074/jbc.M301082200.

Tsai, Y.C., A. Mendoza, J.M. Mariano, M. Zhou, Z. Kostova, B. Chen, T. Veenastra, S.M. Hewitt, J.L. Helman, S.H. Kharma, and A.M. Weissman. 2007. The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat. Med. 13:1504–1509. doi:10.1038/nm1686.

Vanoni, O., P. Pagani, and M. Molinari. 2008. Consequences of individual N-glycan deletions and of proteasomal inhibition on secretion of active BACE. Mol. Cell. 33:608–609. doi:10.1016/j.molcel.2008.03.059.

Vashist, S., and D.T. Ng. 2004. Misfolded proteins are sorted by a sequential checkpoint mechanism of ER quality control. J. Cell Biol. 165:41–52. doi:10.1083/jcb.200309132.

Vij, N., S. Fang, and P.L. Zeitlin. 2006. Selective inhibition of endoplasmic reticulum-associated degradation rescues Delta508 cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J. Biol. Chem. 281:17369–17378. doi:10.1074/jbc.M600509200.

Wang, S., and D.T. Ng. 2008. Lectins sweet-talk proteins into ERAD. Nat. Cell Biol. 10:251–253. doi:10.1038/ncb1308-251.

Wang, Q., L. Li, and Y. Ye. 2006. Regulation of retrotranslocation by gp78-associated deubiquitinating enzyme ataxin-3. J. Cell Biol. 174:963–971. doi:10.1083/jcb.200506100.

Wang, L., H. Dong, C.J. Soroka, N. Wei, J.L. Boyer, and M. Hochstrasser. 2008. Degradation of the bile salt export pump at endoplasmic reticulum in progressive familial intrahepatic cholestasis type II. Hepatology. 48:1585–1599. doi:10.1002/hep.2249.

Wilker, M.G. Forte, and C.J. Stirling. 2006. Sec61p is required for ER-L: genetic dissection of the translocation and ERAD functions of Sec61p using novel derivatives of CPY. J. Biol. Chem. 281:33833–33888. doi:10.1074/jbc.M600505200.

Yagishita, N., K. Ohmeda, T. Amano, S. Yamasaki, A. Sugira, K. Tsuchimochi, H. Shin, K. Kawahara, O. Ohmeda, T. Ohta, et al. 2005. Essential role of synoviolin in embryogenesis. J. Biol. Chem. 280:7909–7916. doi:10.1074/jbc.M410633200.

Yang, M., S. Oinuma, J.S. Bonifacino, and A.M. Weissman. 1998. Novel aspects of degradation of T cell receptor subunits from the endoplasmic reticulum (ER) in T cells: importance of oligosaccharide processing, ubiquitination, and proteasome-dependent removal from ER membranes. J. Exp. Med. 187:835–846. doi:10.1083/jem.187.8.835.

Yang, H., X. Zhong, P. Ballar, S. Luo, Y. Shen, D.C. Rubinsztein, M.J. Monteiro, and S. Fang. 2007. Ubiquitin ligase Hrd1 enhances the degradation and suppresses the toxicity of polyglutamine-expanded huntingtin. Exp. Cell Res. 313:538–550. doi:10.1016/j.yexcr.2006.10.031.

Yoshioka, H. 2007. ER stress and diseases. FEBS J. 274:630–658. doi:10.1111/j.1742-4658.2007.06539.x.

Younger, J.M., L. Chen, H.Y. Ren, M.F. Rosser, E.L. Turnbull, C.Y. Fan, C. Patterson, and D.M. Cyr. 2006. Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator. Cell. 126:571–582. doi:10.1016/j.cell.2006.06.041.

Zhong, X., Y. Shen, P. Ballar, A. Apostolou, R. Agami, and S. Fang. 2004. AAA ATPase gp78/valosin-containing protein interacts with gp78, a ubiquitin ligase for endoplasmic reticulum-associated degradation. J. Biol. Chem. 279:45676–45684. doi:10.1074/jbc.M409342200.